Live Chat ×
Skip to main content

Independent Study with an Expert: Uterine Mesenchymal Tumors with Deceptively Bland Morphology



Original release date:
November 5, 2020 
Access to this course expires on:  May 5, 2021 at 11:59 PM Pacific Time
CME 1.25

Course Description
This session reviews uterine mesenchymal tumors with deceptively bland morphology that mimic variants of leiomyoma yet may carry malignant potential (inflammatory myofibroblastic tumor, PEComa, NTRK fusion sarcoma), recurrent potential (leiomyoma with bizarre nuclei) or risk for hereditary syndrome (tuberous sclerosis complex, hereditary leiomyoma renal cell carcinoma syndrome). A pattern-based approach (spindle cell pattern, epithelioid pattern, myxoid pattern) will be used to provide practical strategies for morphologic evaluation and for selection of immunohistochemical and molecular tests.

Target Audience
Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Apply morphologic and immunohistochemical criteria to distinguish spindle cell, epithelioid, and myxoid variants of uterine leiomyoma from similar-appearing mesenchymal tumors that carry malignant potential
  • Recognize morphologic features of uterine mesenchymal tumors that are associated with increased for tuberous sclerosis complex or hereditary leiomyomatosis renal cell carcinoma syndrome

Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships: Joseph T. Rabban, MD, MPH: Spouse Employee, Merck and Co.

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.